RU2014123622A - Терапевтические и/или диагностические наноносители, нацеленные на матриксные металлопротеазы (ммп) - Google Patents
Терапевтические и/или диагностические наноносители, нацеленные на матриксные металлопротеазы (ммп) Download PDFInfo
- Publication number
- RU2014123622A RU2014123622A RU2014123622A RU2014123622A RU2014123622A RU 2014123622 A RU2014123622 A RU 2014123622A RU 2014123622 A RU2014123622 A RU 2014123622A RU 2014123622 A RU2014123622 A RU 2014123622A RU 2014123622 A RU2014123622 A RU 2014123622A
- Authority
- RU
- Russia
- Prior art keywords
- group
- composition
- targeted delivery
- glycol
- mmp
- Prior art date
Links
- 239000002539 nanocarrier Substances 0.000 title claims abstract 30
- 230000001225 therapeutic effect Effects 0.000 title claims abstract 9
- 102000005741 Metalloproteases Human genes 0.000 title 1
- 108010006035 Metalloproteases Proteins 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 56
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 41
- 125000005647 linker group Chemical group 0.000 claims abstract 19
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract 18
- 239000000032 diagnostic agent Substances 0.000 claims abstract 16
- 229940039227 diagnostic agent Drugs 0.000 claims abstract 16
- 239000003814 drug Substances 0.000 claims abstract 14
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 14
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims abstract 10
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract 10
- 150000001408 amides Chemical class 0.000 claims abstract 10
- 239000004202 carbamide Substances 0.000 claims abstract 10
- 150000002148 esters Chemical class 0.000 claims abstract 10
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims abstract 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract 9
- BEVWMRQFVUOPJT-UHFFFAOYSA-N 2,4-dimethyl-1,3-thiazole-5-carboxamide Chemical compound CC1=NC(C)=C(C(N)=O)S1 BEVWMRQFVUOPJT-UHFFFAOYSA-N 0.000 claims abstract 7
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims abstract 7
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims abstract 7
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 claims abstract 7
- 125000001863 phosphorothioyl group Chemical group *P(*)(*)=S 0.000 claims abstract 7
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims abstract 7
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims abstract 7
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims abstract 6
- 150000001413 amino acids Chemical class 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 21
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 9
- 229940124761 MMP inhibitor Drugs 0.000 claims 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 239000002502 liposome Substances 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000693 micelle Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 3
- GQGVBSHMRYHBTF-UOWFLXDJSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 GQGVBSHMRYHBTF-UOWFLXDJSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- 229930186217 Glycolipid Natural products 0.000 claims 3
- 229940123237 Taxane Drugs 0.000 claims 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 3
- 235000008206 alpha-amino acids Nutrition 0.000 claims 3
- 229960004562 carboplatin Drugs 0.000 claims 3
- 190000008236 carboplatin Chemical compound 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 150000003408 sphingolipids Chemical class 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 239000000232 Lipid Bilayer Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 229920001400 block copolymer Polymers 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 235000018977 lysine Nutrition 0.000 claims 2
- 230000000771 oncological effect Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 238000002626 targeted therapy Methods 0.000 claims 2
- 239000002691 unilamellar liposome Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 150000001841 cholesterols Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 0 *NC(C1(CC*CC1)C(*O)(C1C=C*(Oc2ccccc2)=CC1)[U])=O Chemical compound *NC(C1(CC*CC1)C(*O)(C1C=C*(Oc2ccccc2)=CC1)[U])=O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565461P | 2011-11-30 | 2011-11-30 | |
| US61/565,461 | 2011-11-30 | ||
| PCT/US2012/067236 WO2013082389A1 (en) | 2011-11-30 | 2012-11-30 | Mmp-targeted therapeutic and/or diagnostic nanocarriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014123622A true RU2014123622A (ru) | 2016-01-27 |
Family
ID=47430071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014123622A RU2014123622A (ru) | 2011-11-30 | 2012-11-30 | Терапевтические и/или диагностические наноносители, нацеленные на матриксные металлопротеазы (ммп) |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8871189B2 (enExample) |
| EP (1) | EP2785635A1 (enExample) |
| JP (1) | JP2015502946A (enExample) |
| KR (2) | KR20150107894A (enExample) |
| CN (1) | CN104080729A (enExample) |
| BR (1) | BR112014012746A8 (enExample) |
| CA (1) | CA2854194A1 (enExample) |
| IL (1) | IL232824A0 (enExample) |
| MX (1) | MX2014005749A (enExample) |
| RU (1) | RU2014123622A (enExample) |
| WO (1) | WO2013082389A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2646752C2 (ru) * | 2016-02-25 | 2018-03-07 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Ингибиторы цинк-зависимых металлопротеиназ (ММП-2 и ММП-9) в ряду бензоиламино(фенилсульфонил)-замещенных циклических аминокислот как потенциальные лекарственные средства, препятствующие постинфарктному ремоделированию левого желудочка сердца |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014151988A1 (en) * | 2013-03-15 | 2014-09-25 | Mallinckrodt Llc | Matrix metalloprotease (mmp) targeted agents for imaging and therapy |
| CA2882268A1 (en) * | 2014-02-17 | 2015-08-17 | The Royal Institution For The Advancement Of Learning / Mcgill University | Polynucleotide-poly(diol) conjugates, process of preparation and uses thereof |
| US20160058705A1 (en) * | 2014-08-28 | 2016-03-03 | Jayakumar Rajadas | Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin |
| KR101683463B1 (ko) * | 2014-12-19 | 2016-12-08 | 서울대학교산학협력단 | 마이크로버블-리포좀-멜라닌 나노입자 복합체 및 이를 포함하는 조영제 |
| CN110072531A (zh) | 2016-10-19 | 2019-07-30 | 阿维夫公司 | 用于治疗心血管相关疾病的爱帕琳的新型聚乙二醇化的脂质体制剂 |
| CN111004195B (zh) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | 卡巴他赛弱碱性衍生物及其制剂 |
| JP7842690B2 (ja) | 2020-02-19 | 2026-04-08 | ナミ セラピューティクス， インコーポレイテッド | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225181A (en) * | 1985-06-07 | 1993-07-06 | The Research Foundation Of State University Of New York | Radiolabeled antiplatelet monoclonal antibody for imaging in-vivo thrombi |
| US6750228B1 (en) * | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| FI113840B (fi) * | 2001-03-26 | 2004-06-30 | Ctt Cancer Targeting Tech Oy | Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa |
| FI20031528A0 (fi) * | 2003-10-17 | 2003-10-17 | Ctt Cancer Targeting Tech Oy | Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi |
| GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
| US20060210549A1 (en) | 2004-09-10 | 2006-09-21 | Srivastava Devendra K | Controlled release liposomes and methods of use |
| US20090022782A1 (en) | 2005-02-25 | 2009-01-22 | National University Corp. Hokkaido University | Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue |
| US20090246142A1 (en) | 2006-03-10 | 2009-10-01 | Massachusetts Institute Of Technology | Triggered Self-Assembly of Nanoparticles In Vivo |
| US7618992B2 (en) * | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| WO2010012473A2 (en) | 2008-07-30 | 2010-02-04 | Charite - Universitätsmedizin Berlin | Hydrolase-specific nanosensors, methods for producing them and uses in molecular imaging |
| WO2010022051A2 (en) | 2008-08-18 | 2010-02-25 | University Of Kansas | Disruptors of early/recycling endosomes |
| CA2757645C (en) | 2009-04-06 | 2018-05-15 | Mayo Foundation For Medical Education And Research | Methods and materials for delivering molecules |
| US9682151B2 (en) | 2009-07-15 | 2017-06-20 | The Regents Of The University Of California | Peptides whose uptake in cells is controllable |
| WO2011139343A2 (en) * | 2010-04-28 | 2011-11-10 | Wu Nian | Amino acid linked peg-lipid conjugates |
-
2012
- 2012-11-29 US US13/689,694 patent/US8871189B2/en not_active Expired - Fee Related
- 2012-11-30 CN CN201280067193.1A patent/CN104080729A/zh active Pending
- 2012-11-30 CA CA2854194A patent/CA2854194A1/en not_active Abandoned
- 2012-11-30 KR KR1020157024031A patent/KR20150107894A/ko not_active Withdrawn
- 2012-11-30 EP EP12806235.3A patent/EP2785635A1/en not_active Withdrawn
- 2012-11-30 KR KR1020147014186A patent/KR20140096080A/ko not_active Withdrawn
- 2012-11-30 JP JP2014544914A patent/JP2015502946A/ja active Pending
- 2012-11-30 BR BR112014012746A patent/BR112014012746A8/pt not_active IP Right Cessation
- 2012-11-30 WO PCT/US2012/067236 patent/WO2013082389A1/en not_active Ceased
- 2012-11-30 RU RU2014123622A patent/RU2014123622A/ru not_active Application Discontinuation
- 2012-11-30 MX MX2014005749A patent/MX2014005749A/es unknown
-
2014
- 2014-05-27 IL IL232824A patent/IL232824A0/en unknown
- 2014-09-18 US US14/490,357 patent/US20150004097A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2646752C2 (ru) * | 2016-02-25 | 2018-03-07 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Ингибиторы цинк-зависимых металлопротеиназ (ММП-2 и ММП-9) в ряду бензоиламино(фенилсульфонил)-замещенных циклических аминокислот как потенциальные лекарственные средства, препятствующие постинфарктному ремоделированию левого желудочка сердца |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014012746A2 (pt) | 2017-06-13 |
| CN104080729A (zh) | 2014-10-01 |
| KR20150107894A (ko) | 2015-09-23 |
| BR112014012746A8 (pt) | 2017-06-20 |
| WO2013082389A1 (en) | 2013-06-06 |
| US20130183236A1 (en) | 2013-07-18 |
| CA2854194A1 (en) | 2013-06-06 |
| JP2015502946A (ja) | 2015-01-29 |
| KR20140096080A (ko) | 2014-08-04 |
| MX2014005749A (es) | 2014-06-05 |
| US20150004097A1 (en) | 2015-01-01 |
| IL232824A0 (en) | 2014-07-31 |
| US8871189B2 (en) | 2014-10-28 |
| EP2785635A1 (en) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502946A5 (enExample) | ||
| Mitchell et al. | Incorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes for multimodal imaging | |
| KR101815030B1 (ko) | 킬레이트 복합 미셀을 가지는 약물 전달체 및 그 응용 | |
| ES2993458T3 (en) | Cross-linked polymer modified nanoparticles | |
| US12083187B2 (en) | Method of treatment for solid tumors containing hypoxia and/or stroma features | |
| US20210393523A1 (en) | Aromatic ring substituted amphiphilic polymers as drug delivery systems | |
| RU2012124266A (ru) | Хелаты марганца и их применение в качестве контрастных агентов в магнитно-резонансной визуализации (mpb) | |
| RU2014153658A (ru) | Липиды для композиций для доставки терапевтических агентов | |
| RU2013105799A (ru) | Липидный бислойный носитель для лекарственных средств и визуализирующих агентов | |
| US20240382614A1 (en) | Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications | |
| JP2009542582A5 (enExample) | ||
| JP7323960B2 (ja) | アミノチオール及びその類似体の改善された保護及び送達のための方法 | |
| AU2022224567A1 (en) | Self-assembling nanoparticles based on amphiphilic peptides | |
| AU2022205106A1 (en) | Dual mode radiotracer and -therapeutics | |
| JP2012518012A5 (enExample) | ||
| EP4479095A1 (en) | Stealth-stabilized lipo-polyamino acids | |
| JP2015502946A (ja) | Ｍｍｐ標的化治療用および／または診断用ナノキャリア | |
| Li et al. | Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy | |
| Lu et al. | Skillfully collaborating chemosynthesis with GOx-enabled tumor survival microenvironment deteriorating strategy for amplified chemotherapy and enhanced tumor ablation | |
| EP3258913A1 (en) | Modified docetaxel liposome formulations and uses thereof | |
| WO2015183876A1 (en) | Bimodal fluorophore-labeled liposomes and associated methods and systems | |
| WO2006065888A3 (en) | Targeted iron chelator delivery system | |
| KR20230160806A (ko) | 이중 모드 방사성 트레이서 및 치료법 | |
| JP2009269855A5 (enExample) | ||
| Nardo et al. | In vivo assessment of triazine lipid nanoparticles as transfection agents for plasmid DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170417 |